Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

Laurent Garderet; Dimitris Ziagkos; Anja van Biezen; Simona Iacobelli; Jürgen Finke; Johan Maertens; Liisa Volin; Per Ljungman; Patrice Chevallier; Jakob Passweg; Nicolaas Schaap; Dietrich Beelen; Arnon Nagler; Didier Blaise; Xavier Poiré; Ibrahim Yakoub-Agha; Stig Lenhoff; Charles Craddock; Rik Schots; Alessandro Rambaldi; Jaime Sanz; Pavel Jindra; Ghulam J. Mufti; Marie Robin; Nicolaus Kröger

doi:10.1016/j.bbmt.2017.11.017

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

Laurent Garderet^*, Dimitris Ziagkos, Anja van Biezen, Simona Iacobelli, Jürgen Finke, Johan Maertens, Liisa Volin, Per Ljungman, Patrice Chevallier, Jakob Passweg, Nicolaas Schaap, Dietrich Beelen, Arnon Nagler, Didier Blaise, Xavier Poiré, Ibrahim Yakoub-Agha, Stig Lenhoff, Charles Craddock, Rik Schots, Alessandro RambaldiJaime Sanz, Pavel Jindra, Ghulam J. Mufti, Marie Robin, Nicolaus Kröger

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.

Original language	English
Journal	BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
DOIs	https://doi.org/10.1016/j.bbmt.2017.11.017
Publication status	Accepted/In press - 1 Jan 2018

Keywords

Allogeneic stem cell transplantation
Del (5q)
MDS

Access to Document

10.1016/j.bbmt.2017.11.017

Cite this

Garderet, L., Ziagkos, D., van Biezen, A., Iacobelli, S., Finke, J., Maertens, J., Volin, L., Ljungman, P., Chevallier, P., Passweg, J., Schaap, N., Beelen, D., Nagler, A., Blaise, D., Poiré, X., Yakoub-Agha, I., Lenhoff, S., Craddock, C., Schots, R., ... Kröger, N. (Accepted/In press). Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. https://doi.org/10.1016/j.bbmt.2017.11.017

@article{f9e9e33214164a6189eac416d51d6535,

title = "Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion",

abstract = "The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.",

keywords = "Allogeneic stem cell transplantation, Del (5q), MDS",

author = "Laurent Garderet and Dimitris Ziagkos and {van Biezen}, Anja and Simona Iacobelli and J{\"u}rgen Finke and Johan Maertens and Liisa Volin and Per Ljungman and Patrice Chevallier and Jakob Passweg and Nicolaas Schaap and Dietrich Beelen and Arnon Nagler and Didier Blaise and Xavier Poir{\'e} and Ibrahim Yakoub-Agha and Stig Lenhoff and Charles Craddock and Rik Schots and Alessandro Rambaldi and Jaime Sanz and Pavel Jindra and Mufti, {Ghulam J.} and Marie Robin and Nicolaus Kr{\"o}ger",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/j.bbmt.2017.11.017",

language = "English",

journal = "BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION",

issn = "1083-8791",

publisher = "Elsevier Inc.",

}

Garderet, L, Ziagkos, D, van Biezen, A, Iacobelli, S, Finke, J, Maertens, J, Volin, L, Ljungman, P, Chevallier, P, Passweg, J, Schaap, N, Beelen, D, Nagler, A, Blaise, D, Poiré, X, Yakoub-Agha, I, Lenhoff, S, Craddock, C, Schots, R, Rambaldi, A, Sanz, J, Jindra, P, Mufti, GJ, Robin, M & Kröger, N 2018, 'Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion', BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. https://doi.org/10.1016/j.bbmt.2017.11.017

TY - JOUR

T1 - Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

AU - Garderet, Laurent

AU - Ziagkos, Dimitris

AU - van Biezen, Anja

AU - Iacobelli, Simona

AU - Finke, Jürgen

AU - Maertens, Johan

AU - Volin, Liisa

AU - Ljungman, Per

AU - Chevallier, Patrice

AU - Passweg, Jakob

AU - Schaap, Nicolaas

AU - Beelen, Dietrich

AU - Nagler, Arnon

AU - Blaise, Didier

AU - Poiré, Xavier

AU - Yakoub-Agha, Ibrahim

AU - Lenhoff, Stig

AU - Craddock, Charles

AU - Schots, Rik

AU - Rambaldi, Alessandro

AU - Sanz, Jaime

AU - Jindra, Pavel

AU - Mufti, Ghulam J.

AU - Robin, Marie

AU - Kröger, Nicolaus

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.

AB - The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.

KW - Allogeneic stem cell transplantation

KW - Del (5q)

KW - MDS

UR - http://www.scopus.com/inward/record.url?scp=85039787955&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.11.017

DO - 10.1016/j.bbmt.2017.11.017

M3 - Article

AN - SCOPUS:85039787955

SN - 1083-8791

JO - BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

JF - BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

ER -

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this